Pretreatment tumor samples from a large phase II trial (IMvigor210) investigating the clinical activity of PD-L1 blockade with atezolizumab in metastatic urothelial cancer (mUC) were used for this integrated evaluation. Here, CD274 is linked to neoplasm.